HOME ·

HENLIUS

Henlius (02696.HK): HLX97 (KAT6A/B Inhibitor) Completes First Patient Dosing in Phase I Clinical Trial for Advanced Solid Tumors
Tags：
HENLIUS02696.HKPhase I clinical trial
2026-05-13
Henlius (02696.HK): Self-Developed KAT6A/B Inhibitor HLX97 Approved for Clinical Trial
Tags：
HENLIUS02696.HKnew drug launch
2026-03-05
HENLIUS(02696.HK): Enters into License Agreement with Eisai, Authorizing Commercialization of Hansoh® for Oncology Indications in Japan
Tags：
HENLIUS02696.HK
2026-02-05
HENLIUS(02696.HK): Completes H-Share Full Circulation, 182.65 Million Unlisted Shares Converted to H-Shares to List Tomorrow
Tags：
HENLIUS02696.HK
2026-02-04
Previous1 2